Phthalimides as anti-inflammatory agents
Hector Mario Heras Martinez1,2, Enrique Barragan1, Kostiantyn O Marichev3
1Department of Chemistry & Physics, Florida Gulf Coast University, Fort Myers, FL, USA.
Future Medicinal Chemistry
|December 31, 2024
Summary
Phthalimide derivatives show significant anti-inflammatory and anticancer properties. This review highlights their synthesis and anti-inflammatory applications, focusing on promising drug candidates like LASSBio 468.
Area of Science:
- Medicinal Chemistry
- Organic Synthesis
- Pharmacology
Background:
- Isoindoline-1,3-dione (phthalimide) derivatives are recognized as valuable pharmacophores.
- Phthalimides exhibit significant biological activities, notably as anticancer and anti-inflammatory agents.
- The structural versatility of phthalimides has led to the development of numerous drug candidates.
Purpose of the Study:
- To review the synthetic methodologies for phthalimide derivatives.
- To explore the anti-inflammatory activities of reported phthalimide compounds.
- To highlight promising phthalimide-based drug candidates for therapeutic development.
Main Methods:
- Review of traditional synthetic routes including reaction of phthalic anhydride with amines/anilines and Gabriel synthesis.
- Analysis of literature data on the anti-inflammatory studies of various phthalimide derivatives.
- Identification and discussion of key phthalimide derivatives with therapeutic potential.
Main Results:
- Established synthetic protocols provide access to a diverse range of phthalimide structures.
- Several phthalimide derivatives demonstrate potent anti-inflammatory effects.
- Commercially available drugs (thalidomide, pomalidomide, lenalidomide) and novel compounds (LASSBio 468, adducts 2, 9, 150, 241, 255, 305) show therapeutic promise.
Conclusions:
- Phthalimide derivatives represent a rich source of compounds with significant anti-inflammatory and anticancer potential.
- Optimized synthetic strategies facilitate the exploration of novel phthalimide analogs.
- Continued research into phthalimide derivatives is crucial for discovering new therapeutic agents.
More Related Videos
06:46Collection of Alfalfa Root Exudates to Study the Impact of Di2-ethylhexyl Phthalate on Metabolite Production
Published on: June 2, 2023
1.6K
06:022-Methacryloyloxyethyl Phosphorylcholine Polymer Treatment of Complete Dentures to Inhibit Denture Plaque Deposition
Published on: December 26, 2016
10.3K
Related Concept Videos
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
83
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
83
01:19Antiasthma Drugs: Leukotriene Modifiers
141
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
141
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
96
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
96
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
97
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
97
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
93
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
93
01:29Drugs for Treatment of Ulcerative Colitis in IBD
100
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
100